One arrow for two targets: potential co-treatment regimens for lymphoma and HIV

Chen, Xue; Jia, Lin; Zhang, Xiuqun; Zhang, Tong; Zhang, Yulin

doi:10.1016/j.blre.2022.100965

Cited by 2 publications

(2 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,32 PD-1/PD-L1 expression in HIV-specific T cells is associated with T-cell exhaustion and HIV reservoir formation, which contributes to viral immune evasion and disease progression. 33 The role of the immune checkpoint signaling axis in virus-and immunodeficiency-associated tumor cell immune evasion is well-established. 8 However, knowledge of PD-1/PD-L1 expression in NHL is heterogeneous and remains controversial in terms of its prognostic implications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Zhao,

Cai,

Xiao

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveImmune tolerance and evasion play a critical role in virus‐driven malignancies. However, the phenotype and clinical significance of programmed cell death 1 (PD‐1) and its ligands, PD‐L1 and PD‐L2, in aggressive acquired immunodeficiency syndrome (AIDS)‐related non‐Hodgkin lymphoma (AR‐NHL) remain poorly understood, particularly in the Epstein–Barr virus (EBV)‐positive subset.MethodsWe used in situ hybridization with EBV‐encoded RNA (EBER) to assess the EBV status. We performed immunohistochemistry and flow cytometry analysis to evaluate components of the PD‐1/PD‐L1/L2 pathway in a multi‐institutional cohort of 58 patients with AR‐NHL and compared EBV‐positive and EBV‐negative cases.ResultsThe prevalence of EBV+ in AR‐NHL was 56.9% and was associated with a marked increase in the expression of PD‐1/PD‐L1/PD‐L2 in malignant cells. Patients with AR‐NHLs who tested positive for both EBER and PD‐1 exhibited lower survival rates compared to those negative for these markers (47.4% vs. 93.8%, p = 0.004). Similarly, patients positive for both EBER and PD‐L1 also demonstrated poorer survival (56.5% vs. 93.8%, p = 0.043). Importantly, PD‐1 tissue‐expression demonstrated independent prognostic significance for overall survival in multivariate analysis and was correlated to elevated levels of LDH (r = 0.313, p = 0.031), increased PD‐1+ Tregs (p = 0.006), and robust expression of EBER (r = 0.541, p < 0.001) and PD‐L1 (r = 0.354, p = 0.014) expression.ConclusionsThese data emphasize the importance of PD‐1‐mediated immune evasion in the complex landscape of immune oncology in AR‐NHL co‐infected with EBV, and contribute to the diagnostic classification and possible definition of immunotherapeutic strategies for this unique subgroup.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Second, the notion that HIV lacks oncogenic potential has recently been challenged 25,32 . PD‐1/PD‐L1 expression in HIV‐specific T cells is associated with T‐cell exhaustion and HIV reservoir formation, which contributes to viral immune evasion and disease progression 33 …”

Section: Discussionmentioning

confidence: 99%

Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Zhao,

Cai,

Xiao

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Lymphomas in People Living with HIV

Vaccher

Gloghini

Volpi

et al. 2022

Hemato

View full text Add to dashboard Cite

Lymphomas in people living with HIV (PLWH) are associated with Epstein Barr virus (EBV) and Kaposi-sarcoma-associated herpesvirus (KSHV). They include primary effusion lymphoma, large B-cell lymphoma arising in multicentric Castleman disease, plasmablastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma (HL). Inclusion of these lymphomas in the WHO classification of tumors of hematopoietic and lymphoid tissues and the increasing recognition of these disorders have resulted in established clinical management that has led to improved outcomes. In this review, we report on the current management in lymphomas occurring in PLWH with an emphasis on KSHV-associated disorders and EBV-related HL. We also report on the simultaneous occurrence of KSHV- and EBV-associated disorders and highlight preventive measures that have been planned for tumor prevention in PLWH. In conclusion, it is recommended that treatment choice for PLWH affected by lymphoma, and receiving effective combined antiretroviral therapy (cART), should not be influenced by HIV status. Moreover, there is an urgent need (1) to reduce the current large disparities in health care between HIV-infected and HIV-uninfected populations, (2) to disseminate effective treatment, and (3) to implement preventive strategies for PLWH.

show abstract

One arrow for two targets: potential co-treatment regimens for lymphoma and HIV

Cited by 2 publications

References 88 publications

Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Lymphomas in People Living with HIV

Contact Info

Product

Resources

About